Desai J - Search Results

1

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.

Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Van Cutsem E, et al. Among authors: desai j. J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20. J Clin Oncol. 2019. PMID: 30892987 Free PMC article. Clinical Trial.

2

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.

Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J. Tie J, et al. Among authors: desai j. Int J Cancer. 2011 May 1;128(9):2075-84. doi: 10.1002/ijc.25555. Int J Cancer. 2011. PMID: 20635392

3

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.

Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Tran B, et al. Among authors: desai j. Cancer. 2011 Oct 15;117(20):4623-32. doi: 10.1002/cncr.26086. Epub 2011 Mar 31. Cancer. 2011. PMID: 21456008 Free PMC article.

4

Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation.

Rischin D, Bibby DC, Chong G, Kremmidiotis G, Leske AF, Matthews CA, Wong SS, Rosen MA, Desai J. Rischin D, et al. Among authors: desai j. Clin Cancer Res. 2011 Aug 1;17(15):5152-60. doi: 10.1158/1078-0432.CCR-11-0937. Epub 2011 Jun 20. Clin Cancer Res. 2011. PMID: 21690571 Clinical Trial.

5

An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer.

Voskoboynik M, Bae S, Ananda S, Desai J, Kosmider S, Gibbs P. Voskoboynik M, et al. Among authors: desai j. Ann Oncol. 2012 Oct;23(10):2633-2637. doi: 10.1093/annonc/mds184. Epub 2012 Jun 24. Ann Oncol. 2012. PMID: 22734008 Free article.

6

Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.

Clarke SJ, Karapetis CS, Gibbs P, Pavlakis N, Desai J, Michael M, Tebbutt NC, Price TJ, Tabernero J. Clarke SJ, et al. Among authors: desai j. Crit Rev Oncol Hematol. 2013 Feb;85(2):121-35. doi: 10.1016/j.critrevonc.2012.06.001. Epub 2012 Jul 2. Crit Rev Oncol Hematol. 2013. PMID: 22762963 Review.

7

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Mao M, et al. Among authors: desai j. Clin Cancer Res. 2013 Feb 1;19(3):657-67. doi: 10.1158/1078-0432.CCR-11-1446. Epub 2012 Dec 18. Clin Cancer Res. 2013. PMID: 23251002 Free PMC article.

8

Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Goldstein J, et al. Among authors: desai j. Ann Oncol. 2014 May;25(5):1032-8. doi: 10.1093/annonc/mdu100. Epub 2014 Feb 27. Ann Oncol. 2014. PMID: 24585723 Free PMC article.

9

A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.

Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J. Day F, et al. Among authors: desai j. Target Oncol. 2015 Mar;10(1):99-109. doi: 10.1007/s11523-014-0319-8. Epub 2014 May 27. Target Oncol. 2015. PMID: 24859797 Free PMC article.

10

Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.

Tie J, Desai J. Tie J, et al. Among authors: desai j. Target Oncol. 2015 Jun;10(2):179-88. doi: 10.1007/s11523-014-0330-0. Epub 2014 Aug 15. Target Oncol. 2015. PMID: 25119972 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

923 results

Search Page

Filters